NCT07134413Not yet recruitingPhase 2

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

Efficacy and Safety of QL1706 and Bevacizumab With or Without Chemotherapy in Patients With Non-Squamous Non-Small Cell Lung Cancer Previously Treated With Immune Checkpoint Inhibitors

Source: ClinicalTrials.gov · Last updated 21 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this clinical trial is to evaluate QL1706 plus bevacizumab with or without chemotherapy in patients with PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously treated with immune checkpoint inhibitors (ICIs). The primary objectives are: To assess the efficacy and safety of QL1706 combined with bevacizumab (± chemotherapy) in this population. Eligible patients with PD-L1-negative, locally advanced or metastatic non-squamous NSCLC who progressed after prior PD-1/PD-L1 inhibitor therapy will be assigned to one of two treatment arms at the investigator's discretion: Arm 1: QL1706 + bevacizumab + chemotherapy (target enrollment: 67 subjects). Single-agent chemotherapy (selected from regimens not previously received) will be administered, with options including nab-paclitaxel, pemetrexed, or docetaxel. Arm 2: QL1706 + bevacizumab (target enrollment: 10 subjects).

Status (registry): Not yet recruiting
Phase (registry): Phase 2
Study type: Interventional
Enrollment: 77 (estimated)
First submitted: 14 Aug 2025
Start date: Aug 2025
Primary completion date: Oct 2027
Lead sponsor: Guangdong Association of Clinical Trials
Diseases: Lung cancer
NCT number: NCT07134413

What you commit to

Study type: Interventional · Phase 2
Planned participants: 77
From Aug 2025 to the primary completion date, Oct 2027
No sites listed in no country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Prior lines of systemic anti-tumor therapy ≥ 2.

Other illness

Patients with symptomatic, neurologically unstable central nervous system (CNS) metastases, or CNS diseases that require increased steroid doses to control

Lab values

Known presence of sensitizing mutations in EGFR, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, RET fusions, NTRK fusions, BRAF V600E mutations, MET exon 14 skipping mutations, or HER2 sensitizing mutations (for other genetic alterations, eligibility will be determined by the Biomarker Committee on a case-by-case basis).

Who the study is looking for

Signed an informed consent form
Patients aged ≥18
Histologically or cytologically confirmed stage III or IV non-squamous non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer (AJCC) 8th Edition staging system
at least one measurable lesion according to RECIST 1.1 criteria
ECOG PS 0-1.
Subjects must have adequately documented disease progression following prior treatment with PD-1/PD-L1 inhibitors (administered as monotherapy or in combination with chemotherapy)
- 8\. The most recent tumor tissue sample prior to the first dose of the study drug demonstrated PD-L1 TPS \<1% 9. appropriate organ function

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.